Amanta Healthcare Limited (NSE: AMANTA, BSE: 544502) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹761 Cr, it ranks #1,746 by market cap among the 6,197 Indian listed companies on FinBizNet, and #25 of 63 in Pharmaceuticals. At ₹233.22 (as of 16 Nov 2026), the share price is 3.6% below its 52-week high of ₹241.89 and 145.4% above its 52-week low of ₹95.03. The share price is up 95.2% over one year and up 53.0% over three months.
| Current Price | ₹233.22 |
|---|---|
| Market Cap | ₹761 Cr |
| NSE Symbol | AMANTA |
| BSE Code | 544502 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 52.4 |
| Return on Equity | 6.76% |
| Return on Assets | 5.50% |
| 52-Week Range | ₹95.03 – ₹241.89 |
| 1-Year Price Change | +95.2% |
| 3-Month Price Change | +53.0% |
| Beta (1Y) | 0.17 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.amanta.co.in |
| Revenue | ₹83 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 5.8% |
| EPS (Basic) | ₹1.25 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Amanta Healthcare Limited reported revenue of ₹83 Cr in Q2 FY27, up 17.3% from ₹71 Cr in Q2 FY26 and up 20.8% from ₹69 Cr in Q1 FY27. It posted a net profit of ₹5 Cr for the quarter, against a net profit of ₹1 Cr in Q2 FY26 (up 301.7%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹65 Cr (Q1 FY26) to ₹83 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹83 Cr | ₹5 Cr | 5.8% |
| Q1 FY27 | ₹69 Cr | ₹3 Cr | 4.8% |
| Q4 FY26 | ₹77 Cr | ₹6 Cr | 7.2% |
| Q3 FY26 | ₹74 Cr | ₹5 Cr | 6.2% |
| Q2 FY26 | ₹71 Cr | ₹1 Cr | 1.7% |
| Q1 FY26 | ₹65 Cr | ₹4 Cr | 5.4% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 63.80% of Amanta Healthcare Limited's shares as of Sept 2026, against 63.56% in Sept 2025 (+0.24 percentage points). Delivery averaged 45.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering wit
1. Manufacturing and sale of pharmaceutical products-This segment engages in the development, manufacture, and marketing of various sterile liquid parenteral products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing and sale of pharmaceutical products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Amanta Healthcare Limited | ₹761 Cr | 52.4 | 6.76% | ₹83 Cr | +95.2% |
Listed by market capitalisation. Ratios are shown for context only.
Amanta Healthcare Limited is trading at ₹233.22, with a market capitalisation of ₹761 Cr.
Amanta Healthcare Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Amanta Healthcare Limited has a P/E of 52.4 and a return on equity of 6.76%.
Amanta Healthcare Limited is listed on the NSE under the symbol AMANTA and on the BSE under the scrip code 544502.
Amanta Healthcare Limited's share price is up 95.2% over one year and up 53.0% over three months. Its 52-week range is ₹95.03 to ₹241.89.
In Q2 FY27, Amanta Healthcare Limited reported revenue of ₹83 Cr and net profit of ₹5 Cr, with basic EPS of ₹1.25 (standalone, parsed from the company's exchange filing).
Amanta Healthcare Limited reported revenue of ₹83 Cr in Q2 FY27, up 17.3% from ₹71 Cr in Q2 FY26 and up 20.8% from ₹69 Cr in Q1 FY27.
Promoters held 63.80% of Amanta Healthcare Limited's shares as of Sept 2026, against 63.56% in Sept 2025 (+0.24 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.